# Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

> **NCT02900651** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 139 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** MAK683

## Key facts

- **NCT ID:** NCT02900651
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10-03
- **Primary completion:** 2024-10-09
- **Final completion:** 2024-10-09
- **Target enrollment:** 139 (ACTUAL)
- **Why stopped:** The decision of early termination was made due to business reasons, and was not based on any safety or tolerability concerns for MAK683
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02900651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02900651, "Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02900651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*